## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.5% in mid entry zone (3.0-6.0%), top quartile (78th pct) cross-sectional ranking. Short-term MRS_5 (1.7%) confirms momentum alignment. Strong momentum (+1.7% 5-day acceleration). Outperforming sector by 2.9%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($73.49)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Squarepoint Ops LLC Boosts Holdings in Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251217T110831 | Somewhat-Bullish | Relevance: 100%
- Squarepoint Ops LLC significantly increased its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 724.4% in the second quarter, now owning 46,841 shares valued at $3.42 million. Other institutional investors like Ameriprise Financial Inc. and Norges Bank also made substantial changes to their HSIC holdings. Analyst ratings for Henry Schein are mixed, with an average "Hold" rating and a price target of $76.92.

**2. Westwood Holdings Group Inc. Invests $20.63 Million in Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251215T140618 | Somewhat-Bullish | Relevance: 100%
- Westwood Holdings Group Inc. has acquired a new stake in Henry Schein, Inc. (NASDAQ:HSIC) valued at approximately $20.63 million, purchasing 282,420 shares in the second quarter. Other institutional investors also adjusted their holdings in Henry Schein, with several analysts offering price target adjustments and ratings from "buy" to "hold." The company's stock performance shows a market cap of $9.01 billion and a consensus "Hold" rating from analysts with an average price target of $76.92.

**3. Top 2 Health Care Stocks That May Keep You Up At Night In December**
- Source: Benzinga | 20251216T133242 | Somewhat-Bullish | Relevance: 91%
- This article identifies two healthcare stocks, Henry Schein (HSIC) and Avidity Biosciences (RNA), that might concern investors due to their overbought status indicated by a high Relative Strength Index (RSI). Avidity Biosciences recently missed analyst consensus on quarterly losses but beat sales estimates and announced a merger agreement with Novartis, while Henry Schein received an Overweight rating from Barclays. Investors are advised to consider momentum as a key trading criterion when evaluating these stocks.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $86 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($0.15M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +1.7% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.72 elevated, pricing in significant growth expectations. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.3B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 6.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.72 |
| Forward P/E | 14.5 |
| Current P/E | 15.6 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 2.8% to 4.5% (+1.7% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 78th percentile. MRS_5 at 1.7% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -DUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.52% (CS: 79) | Strong |
| RSI_14 | 64.5 | Neutral |
| MACD Histogram | 0.10 | Bullish |
| vs SMA20 | 1.031x | Above |
| vs SMA50 | 1.099x | Above |
| vs SMA200 | 1.105x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $76.61
- **Stop Loss:** $73.49 (4.1% risk)
- **Target:** $81.29 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 346
- **Position Value:** $26,507.06
- **Portfolio %:** 26.51%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*